Aquestive Therapeutics Liabilities 2024

Aquestive Therapeutics Aktienanalyse

What does Aquestive Therapeutics do?

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Aquestive Therapeutics's Liabilities

Aquestive Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Aquestive Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Aquestive Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Aquestive Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Aquestive Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Aquestive Therapeutics stock

What is the level of liabilities of Aquestive Therapeutics this year?

Aquestive Therapeutics has a debt balance of 163.9 M USD this year.

What were the liabilities of Aquestive Therapeutics compared to the previous year?

The liabilities of Aquestive Therapeutics have increased by -6.67% dropped compared to the previous year.

What are the consequences of high debt for investors of Aquestive Therapeutics?

High liabilities can pose a risk for investors of Aquestive Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Aquestive Therapeutics?

Low liabilities mean that Aquestive Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Aquestive Therapeutics affect the company?

An increase in liabilities of Aquestive Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Aquestive Therapeutics affect the company?

A decrease in the liabilities of Aquestive Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Aquestive Therapeutics?

Some factors that can influence the liabilities of Aquestive Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Aquestive Therapeutics so important for investors?

The liabilities of Aquestive Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Aquestive Therapeutics take to modify the liabilities?

To change its liabilities, Aquestive Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 9/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Aquestive Therapeutics in the year 2023?

In the year 2023, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.